Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07412249
Recruiting Not applicable

Remote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis

NCT07412249 · tracked via the Priya Life Science China tracker
Sponsor
General Hospital of Shenyang Military Region
Phase
Not applicable
Started
2026-03-04
Last updated
2026-04-03

Condition(s) studied

Carotid Stenosis

Investigational drug(s) / intervention(s)

Remote ischemic conditioning

Remote ischemic conditioning: The RIC protocol involves bilateral upper-arm cuff inflation to 200 mmHg (5-min inflation/5-min deflation, 5 cycles) performed 1-2 times daily, starting 3 days before CAS and continuing for 12 months post-procedure.

Study summary

Remote ischemic conditioning (RIC) has emerged as a promising non-invasive strategy to protect the brain, with evidence suggesting its benefit in patients with carotid artery stenting (CAS). However, the long-term benefit and safety of chronic RIC in this population remain unknown. This trial aims to evaluate whether chronic RIC reduces the incidence of major vascular events and improves clinical outcomes in high-risk patients with carotid artery stenosis who received CAS.

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 40 years old; * Patients with symptomatic moderate to severe stenosis of the internal carotid artery; * History of ipsilateral cerebral ischemic symptoms within the past 180 days; * Planned for carotid artery stent; * Essen Score ≥ 3; * Modified Rankin Scale score of 0 or 1; * Signed informed consent. Exclusion Criteria: * Uncontrolled severe hypertension (systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg despite medication) * Subclavian artery stenosis ≥ 50% or presence of subclavian steal syndrome * Severe hematological disorders or significant coagulation abnormalities * Contraindications to remote ischemic conditioning, such as severe soft tissue injury, fracture, or vascular injury in the upper limbs, or peripheral vascular disease in the distal upper limbs * Severe comorbid conditions with a life expectancy of less than 1 year * Participation in another clinical trial within the past 3 months or ongoing participation * Any other circumstances deemed by the investigator as unsuitable for participation in this clinical study.

Primary outcome measure(s)

  • time to the first occurrence of any component of the composite endpoint within 12 months post-randomization — 1 year
    the composite endpoint includes ischemic stroke, hemorrhagic stroke, myocardial infarction \[including coronary revascularization\], TIA, or vascular death

Trial sites (1)

FacilityCityRegionStatus
Department of Neurology, General Hospital of Northern Theater Command Shenyang China Recruiting

More General Hospital of Shenyang Military Region trials in China

Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2) Recruiting
Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD Active, not recruiting
Trendelenburg Position for Acute Anterior Circulation Ischemic Stroke With Large Artery Atherosclerosis Etiology (HOPES 3) Recruiting
Transcranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS) Recruiting
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) Recruiting

Other trials for the same condition

Risk Prediction Model for Cerebrovascular Events in Carotid Artery Stenosis Enrolling by invitation
Endovascular Treatment of Cerebrovascular Diseases Guided by Optical Coherence Tomography (OCT) Technology（CVD-OCT） Active, not recruiting
Optical Coherence Tomography-Assisted Strategy for Interventional Management of Symptomatic Carotid Stenosis (OASIS-C) Starting soon
Research on Ultrasound Diagnostic Criteria for Intracranial and Extracranial Arterial Serial Stenosis Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07412249 on ClinicalTrials.gov ↗ ← All trials in China